Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Allarity Therapeutics Inc

ALLR ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$1.33

▼ -4.32%

Market Cap $21.16M · Vol 3.44K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$21.16M

Micro Cap

Div Yield

N/A

EPS Growth

-17.95%

YoY

RSI (14)

50.00

Momentum

Beta

0.53

vs Market

52W High

$2.35

43.40% below

52W Low

$0.77

72.73% above

Volume

3.44K

Avg 9.85K

P/B

1.77

Price-to-book

ROE

N/A

Return on equity

Free Float

99.84%

Public shares

Shariah Compliance8 STANDARDS

✗ Allarity Therapeutics Inc (ALLR) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ALLR pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-1.48%

+11.76%

-24.86%

+33.01%

YTD

+23.15%

+41.31%

-99.86%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$320.00K
Net Income	$-11,231,000.00
Revenue Growth (YoY)	N/A
Gross Margin	100.00%
Operating Margin	-3,939.06%
Net Profit Margin	-3,509.69%
ROE	N/A
ROA · ROIC	-54.91% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	48.53
P/B	1.77
P/FCF	N/A
EPS Growth	-17.95%
Outstanding Shares	15.91M

Technical Indicators

50-Day SMA	$1.29
200-Day SMA	$1.23
RSI (14)	50.00
Beta	0.53
52-Week High	$2.35
52-Week Low	$0.77

Volume Today	3.44K
Avg Daily Volume (30D)	9.85K
Relative Volume	0.35x
Volatility (10D)	47.54
Volatility (30D)	50.24
Free Float	99.84%

Analyst Consensus

BUY

Current Price $1.33

Mean Target $10.25

52W Low$0.77 52W High$2.35

Current

Target

$0.77 $2.35

Current Analyst target

+670.68% upside potential · 1 analysts

Identifiers

ExchangeNasdaq

FIGIBBG012NXCZQ7

ISINUS0167445008

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 14, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd +3.29% ARGX.BR argenx SE +1.74% ARGX argenx SE +0.83% 2269.HK WuXi Biologics (Cayman) Inc +7.41% INSM Insmed Inc -0.07%

Company Profile

Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. It is focused on development of stenoparib, a PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP technology to develop a companion diagnostic that can be used to select those patients expected to derive clinical benefit from stenoparib. Its therapeutic candidate, stenoparib, is a dual inhibitor of the key DNA damage repair enzyme PARP, as well as Tankyrases, critical enzymes involved in the WNT signaling pathway commonly activated in many cancers. Inhibition of key DNA damage repair enzymes, such as PARP, has clinically demonstrated to be therapeutically beneficial in the treatment of cancers (ovarian cancers). The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes.